Vemurafenib in combination with cobimetinib

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Haematological Malignancy

Drug Information

Target Indication

Haematological Malignancy

Clinical Trial

Last updated: 10/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA2/17/2012

Zelboraf

Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Related Pipeline

Breast Cancer

Rectal Cancer

Breast Cancer

HIV Infections

HER2-positive Early Breast Cancer

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts